A 3-year study found that most patients with moderate to severe ulcerative colitis who responded to initial upadacitinib treatment stayed in remission through 96 weeks, with manageable side effects and consistent results across dosage groups.
A randomized trial of 248 hospitalized patients with alcohol use disorder found no significant difference in drinking reduction between oral and injectable naltrexone.
Researchers found that vitamin B12 reduced cell death in the pancreas and improved energy levels in mouse models of acute pancreatitis, suggesting a potential protective role.
A new study found colon cancer patients with cannabis use disorder were more than 10 times more likely to die within five years, even after adjusting for age and disease severity.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
In a 72-week study of hepatitis B patients, researchers found liver stiffness declines were driven by improved inflammation, not actual fibrosis regression.
April’s FDA approvals feature first-in-class therapies, targeted biologics, expanded indications, and innovative delivery systems across allergy, endocrinology, rheumatology, oncology, infectious diseases, and more.